SCHEMBL3304485

SCHEMBL3304485

Fc1cccc(CBr)c1CBr

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 3/20 0.36
IDO1 P14902 2/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 1/20 0.32
MAOB P27338 1/20 0.32
GPR84 Q9NQS5 2/20 0.31
AOC3 Q16853 1/20 0.31
FFAR1 O14842 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121801 0.85 TAAR1 (0.43) TAAR1HTTKDM4EGAAALDH1A1
SCHEMBL27383 0.85 TAAR1 (0.39) TAAR1HTTKDM4EIDO1GAA
SCHEMBL8127229 0.85 TAAR1 (0.38) TAAR1HTTKDM4EIDO1GAA
SCHEMBL18984003 0.85 GABRA1 (0.46) TAAR1HTTKDM4EALDH1A1SMN1; SMN2
SCHEMBL11029574 0.82 TAAR1 (0.41) TAAR1HTTKDM4EGAAALDH1A1
Hydrochloric Acid SCHEMBL29184016 0.82 TAAR1 (0.41) TAAR1HTTKDM4EIDO1GAA
SCHEMBL338177 0.82 GABRA1 (0.38) ALDH1A1TSHRGABRA1GABRB2
SCHEMBL5973961 0.80 TAAR1 (0.39) TAAR1HTTKDM4EIDO1ALDH1A1
SCHEMBL1636607 0.78 CXCL8 (0.50) KDM4EALDH1A1
SCHEMBL5734027 0.78 TAAR1 (0.39) TAAR1IDO1GAAALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
EP-4023294-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Cognition Therapeutics, Inc. (US) 2022-07-06 EP disclosed
EP-3055301-B1 (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES KADMON CORP LLC (US) 2019-11-20 EP disclosed
EP-3055301-B1 (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES KADMON CORP LLC (US) 2019-11-20 EP disclosed
EP-3498692-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE Cognition Therapeutics, Inc. (US) 2019-06-19 EP disclosed
EP-3099296-B1 ISOINDOLINE DERIVATIVE, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS INC (US) 2019-01-30 EP disclosed
CN-104903312-B RHO kinase inhibitor 卡德门企业有限公司 2019-01-29 CN disclosed
US-10125144-B2 Rho kinase inhibitors KADMON CORPORATION, LLC (US) 2018-11-13 US disclosed
US-20180086703-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2018-03-29 US disclosed
US-20040049038-A1 Sulfamides as gamma-secretase inhibitors MERCK SHARP & DOHME (UK) LIMITED (GB) 2004-03-11 US disclosed
EP-1334085-A1 SULFAMIDES AS GAMMA-SECRETASE INHIBITORS MERCK SHARP & DOHME LTD. (GB) 2003-08-13 EP disclosed
WO-2002036555-A1 SULFAMIDES AS GAMMA-SECRETASE INHIBITORS MERCK SHARP & DOHME LIMITED (GB) 2002-05-10 WO disclosed
US-5698580-A TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS RATIONAL DRUG DESIGN LABORATORIES (JP) 1997-12-16 US disclosed
EP-0770609-A1 ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT Rational Drug Design Laboratories (JP) 1997-05-02 EP disclosed
US-5026856-A Bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1991-06-25 US disclosed
EP-0343560-A2 Isoindoline derivative WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1989-11-29 EP disclosed
US-4217302-A INSECTICIDES, MITICIDES ZOECON CORPORATION (US) 1980-08-12 US disclosed
US-4189598-A INSECTICIDES., MITICIDE ZOECON CORPORATION (US) 1980-02-19 US disclosed
US-4178293-A Isoindolinyl derivatives ZOECON CORPORATION (US) 1979-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease TMEM97, SLC18A2, PSD TAAR1 367/4885HTT 377/4885KDM4E 4636/4885
US-10125144-B2 Rho kinase inhibitors ROCK2, ROCK1, RHOA TAAR1 4156/4885HTT 2935/4885KDM4E 1873/4885
US-20180086703-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, PSD TAAR1 367/4885HTT 377/4885KDM4E 4636/4885
US-20040049038-A1 Sulfamides as gamma-secretase inhibitors BACE1, BACE2, PSEN1 TAAR1 2957/4885HTT 1376/4885KDM4E 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.